The deal was announced in February and Novo Nordisk Foundation has since refiled its application to the U.S. FTC seeking regulatory approval for it. Catalent in a regulatory filing on Friday said the companies were in the process of gathering information and documents to respond to FTC's request received on May 2 and intend to continue to cooperate with the regulator. Catalent and Novo Holdings expect to close the deal towards the end of calendar year 2024.
The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent. The deal was announced in February and Novo Nordisk Foundation has since refiled its application to the U.S. FTC seeking regulatory approval for it. Catalent and Novo Holdings expect to close the deal towards the end of calendar year 2024.
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, investment in the fund returned 8.4% after all fees and expenses compared to 10.6% and 5.2% returns for the SP500TR and R2000 during the quarter, respectively. In addition, you […]